Revenue · FY 2026
₹33,653 Cr
▲ 6.08% YoY
EBITDA · FY 2026
₹7,337.82 Cr
▲ 1.85% YoY
Net profit · FY 2026
₹3,502.97 Cr
▲ 0.56% YoY
Authorised capital
₹666.4 Cr
Registered with MCA
Paid-up capital
₹58.08 Cr
Issued & subscribed
Open charges
₹2,000 Cr
Satisfied ₹4,387.54 Cr
Company age
40 yrs
Est. 1986
Employees · EPFO
15,925
Latest available
About Aurobindo Pharma Ltd
Data last updated: 20 December 2025
Aurobindo Pharma Ltd is a public limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 December 1986, the company has been in operation for over 40 years.
Registered with ROC Hyderabad under CIN L24239AP1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA.
Capital: an authorised share capital of ₹666.4 Cr and a paid-up capital of ₹58.08 Cr. Formerly known as Aurobindo Pharma Pvt Ltd. It is led by directors including Adi Reddy Baddigam and Santanu Mukherjee.
Last AGM: 10 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038.
As per the financials filed for FY 2025, the company reported a revenue of ₹32,346 Cr, a growth of 9% compared to the previous year.
The company has a workforce of approximately 15,925 employees as per the latest available data.
The company is associated with 3 brands - Auronext Pharma, Aurobindo Pharma, Tergene Biotech. As per MCA filings, the company has open charges of ₹2,000 Cr and satisfied charges of ₹4,387.54 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.
Company Details of Aurobindo Pharma Ltd
CIN
L24239TG1986PLC015190
Registration Number
015190
Incorporation Date
26 December 1986
ROC
Hyderabad
Listing Status
Listed (BSE: 524804, NSE: AUROPHARMA)
Company Status
Active
Date of Last AGM
10 September 2025
Date of Balance Sheet
31 March 2025
Compliance Status
Active Compliant
Key People
Nityananda Reddy Kambam Managing Director
Madan Mohan Reddy Mettu Whole-Time Director
Santhanam Subramanian Cfo
Contact Details
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressPlot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038
-
IndustryPharma, Drug Formulation & Development
Company report
Aurobindo Pharma Ltd - full intelligence report
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
₹799
₹999
20% off
Secure checkout · GST invoice included
CIN History of Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has one previous CIN (Corporate Identification Number): L24239AP1986PLC015190. The current CIN is L24239TG1986PLC015190, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239TG1986PLC015190 | Current |
| L24239AP1986PLC015190 | Previous |
Associated Brands with Aurobindo Pharma Ltd
Aurobindo Pharma Ltd operates multiple associated brands including Auronext Pharma, Aurobindo Pharma, and Tergene Biotech. These brands represent Aurobindo Pharma Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com | |
| Bio-conjugate technologies for bacterial vaccines and conjugates are developed. | tergene.com | |
| Offers comprehensive outsourced API production services for the pharmaceutical industry. | auronext.com |
Competitors & Alternatives of Aurobindo Pharma Ltd
Brands and companies operating in the same space as Aurobindo Pharma Ltd include Laurus Labs, Biological E, Concord Biotech and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Biological E
|
Vaccines and therapeutics for multiple diseases are developed and marketed. | Hyderabad, India, India | 1953 |
Concord Biotech
|
APIs and enzymes are manufactured through fermentation by the CDMO. | Ahmedabad, India, India | 2000 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
BDR Pharmaceuticals Internationals
|
APIs and finished products are developed and manufactured. | Mumbai, India, India | 2003 |
Insmed
|
Developer of small molecule inhibitors for rare lung diseases | Bridgewater, United States, United States | 1999 |
Vaxart
|
Developer of therapeutic solutions for treating multiple infectious diseases | San Francisco, United States, United States | 2004 |
Almac Group
|
Integrated CDMO services for biopharma R&D and manufacturing are offered. | Craigavon, United Kingdom, United Kingdom | 2001 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Indoco Remedies
|
APIs manufacturing and formulation services are provided in therapeutic segments. | Mumbai, India, India | 1947 |
Business Activity of Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is currently managed by 15 directors, with 27 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Adi Reddy Baddigam | Nodal Officer | 03 Sep 2019 | 6 Years 10 Months | Current |
|
Santanu Mukherjee
Also directs:
Apitoria Pharma Private Limited, Suven Life Sciences Limited, Sumedha Fiscal Services Ltd and 4 more
|
Director | 09 Feb 2023 | 3 Years 4 Months | Current |
|
Deepali Pant Rajeev Joshi
Also directs:
Coromandel International Limited, Lmw Limited, Kan And More Private Limited and 3 more
|
Director | 10 Feb 2024 | 2 Years 4 Months | Current |
|
Nityananda Reddy Kambam
Also directs:
Aurobindo Antibiotics Private Limited, Apl Healthcare Limited, Apitoria Pharma Private Limited and 5 more
|
Managing Director | 30 Dec 1992 | 33 Years 6 Months | Current |
|
Madan Mohan Reddy Mettu
Also directs:
Mss Packaging Industries Llp, Engenra Biologics Private Limited, Curateq Biologics Private Limited and 5 more
|
Whole-Time Director | 01 Jan 2013 | 13 Years 6 Months | Current |
| Venkata Ramprasad Reddy Penaka | Director | 30 Dec 1992 | 33 Years 6 Months | Current |
Showing 6 of 15 current directors. View all directors
Financials of Aurobindo Pharma Ltd FY 2026 filings available
Aurobindo Pharma Ltd reported revenue of ₹33,653 Cr (up 6.08% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
Revenue · FY 2026
₹33,653 Cr
▲ 6.08%
Profit · FY 2026
₹3,502.97 Cr
▲ 0.56%
EBITDA · FY 2026
₹7,337.82 Cr
▲ 1.85%
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹33,653 Cr | ₹31,724 Cr | ₹29,002 Cr | ₹24,855 Cr | ₹23,455 Cr | ₹24,775 Cr | ₹23,099 Cr |
| Other Income | ₹492.09 Cr | ₹621.85 Cr | ₹557.38 Cr | ₹290.59 Cr | ₹320.35 Cr | ₹380.84 Cr | ₹86.2 Cr |
| Total Income | ₹34,145 Cr | ₹32,346 Cr | ₹29,559 Cr | ₹25,146 Cr | ₹23,776 Cr | ₹25,155 Cr | ₹23,185 Cr |
| Cost of Materials Consumed | ₹10,305 Cr | ₹10,737 Cr | ₹10,776 Cr | ₹9,652.51 Cr | ₹7,371.83 Cr | ₹8,317.27 Cr | ₹7,724.98 Cr |
| Purchases of Stock-in-Trade | ₹3,477.98 Cr | ₹2,887.11 Cr | ₹2,772.93 Cr | ₹2,050.43 Cr | ₹1,951.77 Cr | ₹2,315.42 Cr | ₹2,112.11 Cr |
| Changes in Inventories | -₹294.81 Cr | -₹597.63 Cr | -₹946.17 Cr | -₹409.68 Cr | ₹816.68 Cr | -₹730.21 Cr | -₹101.86 Cr |
| Employee Benefit Expense | ₹5,190.17 Cr | ₹4,475.62 Cr | ₹3,922.94 Cr | ₹3,522.25 Cr | ₹3,450.92 Cr | ₹3,535.02 Cr | ₹3,219.18 Cr |
| Finance Costs | ₹383.97 Cr | ₹457.24 Cr | ₹289.71 Cr | ₹140.48 Cr | ₹48.64 Cr | ₹74.49 Cr | ₹159.77 Cr |
| Depreciation & Amortisation | ₹1,778.19 Cr | ₹1,649.42 Cr | ₹1,521.66 Cr | ₹1,244.58 Cr | ₹1,126.52 Cr | ₹1,055.38 Cr | ₹966.71 Cr |
| Other Expenses | ₹8,128.82 Cr | ₹7,639.08 Cr | ₹6,633.03 Cr | ₹6,321.23 Cr | ₹5,477.52 Cr | ₹6,003.72 Cr | ₹5,319.49 Cr |
| Total Expenses | ₹28,970 Cr | ₹27,248 Cr | ₹24,970 Cr | ₹22,522 Cr | ₹20,244 Cr | ₹20,571 Cr | ₹19,400 Cr |
| Profit Before Exceptional Items & Tax | ₹5,175.66 Cr | ₹5,097.98 Cr | ₹4,589.01 Cr | ₹2,624.17 Cr | ₹3,531.96 Cr | ₹4,584.38 Cr | ₹3,784.32 Cr |
| Exceptional Items | -₹65.33 Cr | ₹0 | -₹191.86 Cr | ₹0 | -₹127.97 Cr | ₹2,814.58 Cr | -₹26.13 Cr |
| Profit Before Tax | ₹5,110.33 Cr | ₹5,097.98 Cr | ₹4,397.15 Cr | ₹2,624.17 Cr | ₹3,403.99 Cr | ₹7,398.96 Cr | ₹3,758.19 Cr |
| Total Tax Expense | ₹1,608.88 Cr | ₹1,582.72 Cr | ₹1,211.02 Cr | ₹684.85 Cr | ₹725.63 Cr | ₹2,009.77 Cr | ₹913.51 Cr |
| Net Profit | ₹3,502.97 Cr | ₹3,483.57 Cr | ₹3,168.97 Cr | ₹1,927.65 Cr | ₹2,647.11 Cr | ₹5,333.83 Cr | ₹2,829.51 Cr |
| attributable to Owners | ₹3,504.75 Cr | ₹3,485.88 Cr | ₹3,172.97 Cr | ₹1,927.5 Cr | ₹2,648.15 Cr | ₹5,338.58 Cr | ₹2,830.97 Cr |
| attributable to NCI | -₹1.78 Cr | -₹2.31 Cr | -₹4 Cr | ₹15 Lakh | -₹1.04 Cr | -₹1.02 Cr | -₹1.46 Cr |
| Other Comprehensive Income | ₹1,965.2 Cr | ₹303.62 Cr | ₹99.16 Cr | ₹735.58 Cr | ₹261.65 Cr | ₹4.74 Cr | ₹287.12 Cr |
| Total Comprehensive Income | ₹5,468.17 Cr | ₹3,787.19 Cr | ₹3,268.13 Cr | ₹2,663.23 Cr | ₹2,908.76 Cr | ₹5,338.57 Cr | ₹3,116.63 Cr |
| EBITDA (computed) | ₹7,337.82 Cr | ₹7,204.64 Cr | ₹6,400.38 Cr | ₹4,009.23 Cr | ₹4,707.12 Cr | ₹5,714.25 Cr | ₹4,910.8 Cr |
| Basic EPS | ₹60.34 | ₹59.81 | ₹54.16 | ₹32.90 | ₹45.19 | ₹91.04 | ₹48.32 |
| Diluted EPS | ₹60.34 | ₹59.81 | ₹54.16 | ₹32.90 | ₹45.19 | ₹91.04 | ₹48.32 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹58,502 Cr | ₹49,785 Cr | ₹45,072 Cr | ₹39,890 Cr |
| Non-current Assets | ₹25,793 Cr | ₹22,623 Cr | ₹20,866 Cr | ₹18,344 Cr |
| Current Assets | ₹32,709 Cr | ₹27,162 Cr | ₹23,772 Cr | ₹21,546 Cr |
| Property, Plant & Equipment | ₹14,330 Cr | ₹12,189 Cr | ₹11,546 Cr | ₹7,995.38 Cr |
| Inventories | ₹12,053 Cr | ₹10,544 Cr | ₹9,808.23 Cr | ₹8,511.23 Cr |
| Trade Receivables | ₹7,094.37 Cr | ₹5,745.93 Cr | ₹4,816.74 Cr | ₹4,466.38 Cr |
| Cash & Equivalents | ₹7,191.4 Cr | ₹5,568.95 Cr | ₹3,393.48 Cr | ₹4,396.29 Cr |
| Equity (Net Worth) | ₹37,883 Cr | ₹32,647 Cr | ₹29,851 Cr | ₹26,852 Cr |
| Equity Share Capital | ₹58.08 Cr | ₹58.08 Cr | ₹58.59 Cr | ₹58.59 Cr |
| Borrowings (Non-current) | ₹802.75 Cr | ₹1,561.65 Cr | ₹2,134.9 Cr | ₹618.96 Cr |
| Borrowings (Current) | ₹6,873.45 Cr | ₹6,380.03 Cr | ₹4,180.32 Cr | ₹4,242.56 Cr |
| Total Debt (computed) | ₹7,676.2 Cr | ₹7,941.68 Cr | ₹6,315.22 Cr | ₹4,861.52 Cr |
| Current Liabilities | ₹18,039 Cr | ₹14,682 Cr | ₹12,199 Cr | ₹11,494 Cr |
| Total Liabilities | ₹20,619 Cr | ₹17,138 Cr | ₹15,221 Cr | ₹13,038 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹5,526.37 Cr | ₹3,924.62 Cr | ₹2,434.52 Cr | ₹2,386.75 Cr | ₹5,016.48 Cr |
| Investing Cash Flow | -₹3,458.43 Cr | -₹1,875.14 Cr | -₹4,255.95 Cr | -₹3,977.75 Cr | -₹3,214.81 Cr |
| Financing Cash Flow | -₹1,269.15 Cr | ₹119.78 Cr | ₹800.42 Cr | ₹1,814.41 Cr | -₹2,969.27 Cr |
| Capital Expenditure | ₹2,685.77 Cr | ₹1,967.86 Cr | ₹2,780.33 Cr | ₹2,403.8 Cr | ₹2,052.91 Cr |
| Free Cash Flow (computed) | ₹2,840.6 Cr | ₹1,956.76 Cr | -₹345.81 Cr | -₹17.05 Cr | ₹2,963.57 Cr |
| Dividends Paid | ₹232.4 Cr | ₹0 | ₹263.64 Cr | ₹439.53 Cr | ₹263.7 Cr |
| Net Change in Cash | ₹1,627.61 Cr | ₹2,178.36 Cr | -₹1,006.84 Cr | ₹223.35 Cr | -₹1,167.4 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹8,853.34 Cr | ₹8,645.9 Cr | ₹8,285.7 Cr | ₹7,868.14 Cr | ₹8,382.12 Cr | ₹7,978.52 Cr | ₹7,796.07 Cr | ₹7,567.02 Cr | ₹7,580.15 Cr | ₹7,351.78 Cr | ₹7,219.42 Cr | ₹6,850.52 Cr |
| Other Income | ₹117.04 Cr | ₹187.64 Cr | ₹120.59 Cr | ₹105.3 Cr | ₹134.81 Cr | ₹157.29 Cr | ₹136 Cr | ₹220.93 Cr | ₹135.62 Cr | ₹162.52 Cr | ₹186.98 Cr | ₹116.33 Cr |
| Total Income | ₹8,970.38 Cr | ₹8,833.54 Cr | ₹8,406.29 Cr | ₹7,973.44 Cr | ₹8,516.93 Cr | ₹8,135.81 Cr | ₹7,932.07 Cr | ₹7,787.95 Cr | ₹7,715.77 Cr | ₹7,514.3 Cr | ₹7,406.4 Cr | ₹6,966.85 Cr |
| Cost of Materials Consumed | ₹2,505.35 Cr | ₹2,754.88 Cr | ₹2,509.8 Cr | ₹2,535.16 Cr | ₹2,799.51 Cr | ₹2,728.74 Cr | ₹2,741.85 Cr | ₹2,466.66 Cr | ₹2,634.88 Cr | ₹2,675.52 Cr | ₹2,708.91 Cr | ₹2,756.83 Cr |
| Purchases of Stock-in-Trade | ₹931.48 Cr | ₹892.65 Cr | ₹846.05 Cr | ₹807.8 Cr | ₹636.18 Cr | ₹823.89 Cr | ₹747.03 Cr | ₹680.01 Cr | ₹785.95 Cr | ₹775.75 Cr | ₹631.07 Cr | ₹580.16 Cr |
| Changes in Inventories | -₹7.76 Cr | -₹166.32 Cr | -₹16.99 Cr | -₹103.74 Cr | -₹7.81 Cr | -₹237.22 Cr | -₹278.61 Cr | -₹73.99 Cr | -₹359.95 Cr | -₹300.7 Cr | -₹103.24 Cr | -₹182.28 Cr |
| Employee Benefit Expense | ₹1,373.98 Cr | ₹1,310.06 Cr | ₹1,277.33 Cr | ₹1,228.8 Cr | ₹1,162.64 Cr | ₹1,131.55 Cr | ₹1,109.48 Cr | ₹1,071.95 Cr | ₹1,026.32 Cr | ₹989.68 Cr | ₹954.97 Cr | ₹951.97 Cr |
| Finance Costs | ₹98.21 Cr | ₹92.77 Cr | ₹95.24 Cr | ₹97.75 Cr | ₹115.02 Cr | ₹118.48 Cr | ₹112.7 Cr | ₹111.04 Cr | ₹89.43 Cr | ₹75.55 Cr | ₹68.18 Cr | ₹56.55 Cr |
| Depreciation & Amortisation | ₹478.57 Cr | ₹464.73 Cr | ₹429.19 Cr | ₹405.7 Cr | ₹444.43 Cr | ₹418.53 Cr | ₹382.28 Cr | ₹404.18 Cr | ₹354.33 Cr | ₹423.27 Cr | ₹417.5 Cr | ₹326.56 Cr |
| Other Expenses | ₹2,297.51 Cr | ₹2,081.29 Cr | ₹1,991.41 Cr | ₹1,797.09 Cr | ₹1,999.68 Cr | ₹1,953.58 Cr | ₹1,910.18 Cr | ₹1,802.82 Cr | ₹1,820.14 Cr | ₹1,610.22 Cr | ₹1,654.27 Cr | ₹1,592.47 Cr |
| Total Expenses | ₹7,677.34 Cr | ₹7,430.06 Cr | ₹7,132.03 Cr | ₹6,768.56 Cr | ₹7,149.65 Cr | ₹6,937.55 Cr | ₹6,724.91 Cr | ₹6,462.67 Cr | ₹6,351.1 Cr | ₹6,249.29 Cr | ₹6,331.66 Cr | ₹6,082.26 Cr |
| Profit Before Exceptional Items & Tax | ₹1,293.04 Cr | ₹1,403.48 Cr | ₹1,274.26 Cr | ₹1,204.88 Cr | ₹1,367.28 Cr | ₹1,198.26 Cr | ₹1,207.16 Cr | ₹1,325.28 Cr | ₹1,364.67 Cr | ₹1,265.01 Cr | ₹1,074.74 Cr | ₹884.59 Cr |
| Exceptional Items | ₹0 | -₹65.33 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹122.11 Cr | ₹0 | ₹0 | -₹69.75 Cr |
| Profit Before Tax | ₹1,293.04 Cr | ₹1,338.15 Cr | ₹1,274.26 Cr | ₹1,204.88 Cr | ₹1,367.28 Cr | ₹1,198.26 Cr | ₹1,207.16 Cr | ₹1,325.28 Cr | ₹1,242.56 Cr | ₹1,265.01 Cr | ₹1,074.74 Cr | ₹814.84 Cr |
| Total Tax Expense | ₹369.77 Cr | ₹428.72 Cr | ₹427.79 Cr | ₹382.6 Cr | ₹432.26 Cr | ₹354.28 Cr | ₹390.51 Cr | ₹405.67 Cr | ₹322.55 Cr | ₹322.45 Cr | ₹323.7 Cr | ₹242.32 Cr |
| Net Profit | ₹920.84 Cr | ₹909.8 Cr | ₹848.13 Cr | ₹824.2 Cr | ₹902.83 Cr | ₹845.57 Cr | ₹816.95 Cr | ₹918.22 Cr | ₹907.35 Cr | ₹939.97 Cr | ₹751.94 Cr | ₹569.71 Cr |
| attributable to Owners | ₹921.26 Cr | ₹910.29 Cr | ₹848.45 Cr | ₹824.75 Cr | ₹903.47 Cr | ₹854.81 Cr | ₹817.38 Cr | ₹919.22 Cr | ₹908.75 Cr | ₹936.29 Cr | ₹757.18 Cr | ₹570.75 Cr |
| attributable to NCI | -₹42 Lakh | -₹49 Lakh | -₹32 Lakh | -₹55 Lakh | -₹64 Lakh | -₹24 Lakh | -₹43 Lakh | -₹1 Cr | -₹1.4 Cr | ₹3.68 Cr | -₹5.24 Cr | -₹1.04 Cr |
| Other Comprehensive Income | ₹790.56 Cr | ₹227.73 Cr | ₹541.07 Cr | ₹405.84 Cr | ₹139.66 Cr | -₹65.27 Cr | ₹270.28 Cr | -₹41.05 Cr | -₹110.57 Cr | ₹188.7 Cr | ₹51.4 Cr | -₹30.37 Cr |
| Total Comprehensive Income | ₹1,711.4 Cr | ₹1,137.53 Cr | ₹1,389.2 Cr | ₹1,230.04 Cr | ₹1,042.49 Cr | ₹780.3 Cr | ₹1,087.23 Cr | ₹877.17 Cr | ₹796.78 Cr | ₹1,128.67 Cr | ₹803.34 Cr | ₹539.34 Cr |
| EBITDA (computed) | ₹1,869.82 Cr | ₹1,960.98 Cr | ₹1,798.69 Cr | ₹1,708.33 Cr | ₹1,926.73 Cr | ₹1,735.27 Cr | ₹1,702.14 Cr | ₹1,840.5 Cr | ₹1,808.43 Cr | ₹1,763.83 Cr | ₹1,560.42 Cr | ₹1,267.7 Cr |
| Basic EPS | ₹15.86 | ₹15.67 | ₹14.61 | ₹14.20 | ₹15.56 | ₹14.56 | ₹14.00 | ₹15.69 | ₹15.51 | ₹16.04 | ₹12.83 | ₹9.74 |
| Diluted EPS | ₹15.86 | ₹15.67 | ₹14.61 | ₹14.20 | ₹15.56 | ₹14.56 | ₹14.00 | ₹15.69 | ₹15.51 | ₹16.04 | ₹12.83 | ₹9.74 |
Latest 12 quarters shown of 25 on record.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹11,172 Cr | ₹10,933 Cr | ₹10,646 Cr | ₹12,792 Cr | ₹11,287 Cr | ₹15,824 Cr | ₹13,266 Cr |
| Other Income | ₹587.53 Cr | ₹328.12 Cr | ₹616.06 Cr | ₹433.76 Cr | ₹670.99 Cr | ₹589.86 Cr | ₹258.01 Cr |
| Total Income | ₹11,759 Cr | ₹11,261 Cr | ₹11,262 Cr | ₹13,226 Cr | ₹11,958 Cr | ₹16,414 Cr | ₹13,524 Cr |
| Cost of Materials Consumed | ₹5,238.38 Cr | ₹5,610.21 Cr | ₹5,761.08 Cr | ₹7,247.69 Cr | ₹5,783.93 Cr | ₹7,215.73 Cr | ₹6,747.55 Cr |
| Purchases of Stock-in-Trade | ₹73.2 Cr | ₹65.13 Cr | ₹203.4 Cr | ₹89.23 Cr | ₹16.81 Cr | ₹26.09 Cr | ₹5.51 Cr |
| Changes in Inventories | ₹46.55 Cr | -₹67.66 Cr | -₹116.23 Cr | -₹466 Cr | ₹45.51 Cr | ₹2.99 Cr | -₹229.53 Cr |
| Employee Benefit Expense | ₹1,161.15 Cr | ₹1,063.07 Cr | ₹980.56 Cr | ₹1,641.88 Cr | ₹1,600.04 Cr | ₹1,735.43 Cr | ₹1,561.47 Cr |
| Finance Costs | ₹213.15 Cr | ₹230.04 Cr | ₹182.6 Cr | ₹114.98 Cr | ₹16.94 Cr | ₹28.68 Cr | ₹95.58 Cr |
| Depreciation & Amortisation | ₹285.36 Cr | ₹297.2 Cr | ₹254.58 Cr | ₹435.35 Cr | ₹415.26 Cr | ₹487.99 Cr | ₹470.48 Cr |
| Other Expenses | ₹1,560.5 Cr | ₹1,704.98 Cr | ₹1,592.79 Cr | ₹2,548.56 Cr | ₹2,367.45 Cr | ₹2,723.62 Cr | ₹2,495.73 Cr |
| Total Expenses | ₹8,578.29 Cr | ₹8,902.97 Cr | ₹8,858.78 Cr | ₹11,612 Cr | ₹10,246 Cr | ₹12,221 Cr | ₹11,147 Cr |
| Profit Before Exceptional Items & Tax | ₹3,180.96 Cr | ₹2,358.45 Cr | ₹2,402.92 Cr | ₹1,614.35 Cr | ₹1,712.19 Cr | ₹4,193.01 Cr | ₹2,377.7 Cr |
| Exceptional Items | -₹17.38 Cr | ₹0 | ₹0 | ₹0 | -₹74.71 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹3,163.58 Cr | ₹2,358.45 Cr | ₹2,402.92 Cr | ₹1,614.35 Cr | ₹1,637.48 Cr | ₹4,193.01 Cr | ₹2,377.7 Cr |
| Total Tax Expense | ₹748.78 Cr | ₹611.66 Cr | ₹502.82 Cr | ₹383.94 Cr | ₹182.77 Cr | ₹1,080.1 Cr | ₹504.96 Cr |
| Net Profit | ₹2,414.8 Cr | ₹1,746.79 Cr | ₹1,954.14 Cr | ₹1,230.41 Cr | ₹1,454.71 Cr | ₹3,112.91 Cr | ₹1,872.74 Cr |
| Other Comprehensive Income | ₹1.08 Cr | -₹5.26 Cr | -₹1.69 Cr | ₹5.87 Cr | ₹1.69 Cr | -₹6.42 Cr | -₹12.55 Cr |
| Total Comprehensive Income | ₹2,415.88 Cr | ₹1,741.53 Cr | ₹1,952.45 Cr | ₹1,236.28 Cr | ₹1,456.4 Cr | ₹3,106.49 Cr | ₹1,860.19 Cr |
| EBITDA (computed) | ₹3,679.47 Cr | ₹2,885.69 Cr | ₹2,840.1 Cr | ₹2,164.68 Cr | ₹2,144.39 Cr | ₹4,709.68 Cr | ₹2,943.76 Cr |
| Basic EPS | ₹41.58 | ₹29.97 | ₹32.43 | ₹21.00 | ₹24.83 | ₹53.13 | ₹31.96 |
| Diluted EPS | ₹41.58 | ₹29.97 | ₹32.43 | ₹21.00 | ₹24.83 | ₹53.13 | ₹31.96 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹29,279 Cr | ₹27,513 Cr | ₹25,154 Cr | ₹24,934 Cr |
| Non-current Assets | ₹21,258 Cr | ₹19,824 Cr | ₹17,915 Cr | ₹15,210 Cr |
| Current Assets | ₹8,021.88 Cr | ₹7,689.4 Cr | ₹7,239.13 Cr | ₹9,723.64 Cr |
| Property, Plant & Equipment | ₹2,419.93 Cr | ₹2,185.29 Cr | ₹2,222.21 Cr | ₹3,481.88 Cr |
| Inventories | ₹2,360.57 Cr | ₹2,359.28 Cr | ₹2,367.6 Cr | ₹4,125.26 Cr |
| Trade Receivables | ₹4,209.68 Cr | ₹4,195.05 Cr | ₹3,776.59 Cr | ₹4,560.26 Cr |
| Cash & Equivalents | ₹160.43 Cr | ₹295.26 Cr | ₹83.32 Cr | ₹129.65 Cr |
| Equity (Net Worth) | ₹22,718 Cr | ₹20,534 Cr | ₹19,723 Cr | ₹17,914 Cr |
| Equity Share Capital | ₹58.08 Cr | ₹58.08 Cr | ₹58.59 Cr | ₹58.59 Cr |
| Borrowings (Non-current) | ₹0 | ₹400 Cr | ₹0 | ₹0 |
| Borrowings (Current) | ₹4,182.47 Cr | ₹4,225.09 Cr | ₹2,817.84 Cr | ₹4,142.57 Cr |
| Total Debt (computed) | ₹4,182.47 Cr | ₹4,625.09 Cr | ₹2,817.84 Cr | ₹4,142.57 Cr |
| Current Liabilities | ₹6,299.35 Cr | ₹6,420.5 Cr | ₹5,244.74 Cr | ₹6,673.35 Cr |
| Total Liabilities | ₹6,561.69 Cr | ₹6,978.95 Cr | ₹5,431.16 Cr | ₹7,019.48 Cr |
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹2,933.02 Cr | ₹1,645.79 Cr | ₹1,714.8 Cr | ₹1,821.16 Cr | ₹3,726.71 Cr |
| Investing Cash Flow | -₹2,024.96 Cr | -₹2,065.9 Cr | -₹159.96 Cr | -₹3,459.68 Cr | -₹1,613.51 Cr |
| Financing Cash Flow | -₹1,072.35 Cr | ₹616.31 Cr | -₹1,837.03 Cr | ₹1,719.48 Cr | -₹2,447.54 Cr |
| Capital Expenditure | ₹520.61 Cr | ₹246.94 Cr | ₹417.59 Cr | ₹353.75 Cr | ₹614.06 Cr |
| Free Cash Flow (computed) | ₹2,412.41 Cr | ₹1,398.85 Cr | ₹1,297.21 Cr | ₹1,467.41 Cr | ₹3,112.65 Cr |
| Dividends Paid | ₹232.4 Cr | ₹54 Lakh | ₹263.64 Cr | ₹439.53 Cr | ₹263.7 Cr |
| Net Change in Cash | -₹134.83 Cr | ₹211.94 Cr | -₹273.81 Cr | ₹81.44 Cr | -₹335.37 Cr |
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹2,786.55 Cr | ₹2,747.28 Cr | ₹2,789.72 Cr | ₹2,848.17 Cr | ₹2,731.99 Cr | ₹2,916.63 Cr | ₹2,824.59 Cr | ₹2,460.09 Cr | ₹2,894.03 Cr | ₹2,692.03 Cr | ₹2,668.76 Cr | ₹2,390.82 Cr |
| Other Income | ₹214.09 Cr | ₹130.15 Cr | ₹159.52 Cr | ₹83.77 Cr | ₹113.98 Cr | ₹54.26 Cr | ₹122.66 Cr | ₹65.32 Cr | ₹122.97 Cr | ₹331.13 Cr | ₹67.08 Cr | ₹94.88 Cr |
| Total Income | ₹3,000.64 Cr | ₹2,877.43 Cr | ₹2,949.24 Cr | ₹2,931.94 Cr | ₹2,845.97 Cr | ₹2,970.89 Cr | ₹2,947.25 Cr | ₹2,525.41 Cr | ₹3,017 Cr | ₹3,023.16 Cr | ₹2,735.84 Cr | ₹2,485.7 Cr |
| Cost of Materials Consumed | ₹1,251.66 Cr | ₹1,402.55 Cr | ₹1,244.16 Cr | ₹1,340.01 Cr | ₹1,360.7 Cr | ₹1,506.59 Cr | ₹1,424.74 Cr | ₹1,318.18 Cr | ₹1,401.56 Cr | ₹1,465.93 Cr | ₹1,518.33 Cr | ₹1,375.26 Cr |
| Purchases of Stock-in-Trade | ₹16.52 Cr | ₹20.15 Cr | ₹22.15 Cr | ₹14.38 Cr | ₹16.31 Cr | ₹19.06 Cr | ₹16.16 Cr | ₹13.6 Cr | ₹17.01 Cr | ₹155.09 Cr | ₹15.77 Cr | ₹15.53 Cr |
| Changes in Inventories | ₹42.79 Cr | -₹135.99 Cr | ₹101.27 Cr | ₹38.48 Cr | ₹60.52 Cr | -₹61.37 Cr | -₹31.25 Cr | -₹35.56 Cr | -₹13.1 Cr | -₹59.76 Cr | -₹27.12 Cr | -₹16.25 Cr |
| Employee Benefit Expense | ₹292.71 Cr | ₹291.1 Cr | ₹294.37 Cr | ₹282.97 Cr | ₹273.11 Cr | ₹265.15 Cr | ₹265.48 Cr | ₹259.33 Cr | ₹248.91 Cr | ₹248.08 Cr | ₹247.51 Cr | ₹236.06 Cr |
| Finance Costs | ₹47.27 Cr | ₹48.43 Cr | ₹57.45 Cr | ₹60 Cr | ₹61.09 Cr | ₹66.19 Cr | ₹51.63 Cr | ₹51.13 Cr | ₹53.07 Cr | ₹61.25 Cr | ₹36.69 Cr | ₹31.59 Cr |
| Depreciation & Amortisation | ₹71.93 Cr | ₹71.92 Cr | ₹71.49 Cr | ₹70.02 Cr | ₹93.88 Cr | ₹68.28 Cr | ₹68.16 Cr | ₹66.88 Cr | ₹64.81 Cr | ₹64.35 Cr | ₹65.79 Cr | ₹59.63 Cr |
| Other Expenses | ₹401.45 Cr | ₹379.99 Cr | ₹403.07 Cr | ₹375.99 Cr | ₹424.84 Cr | ₹474.05 Cr | ₹428.58 Cr | ₹405.61 Cr | ₹464.86 Cr | ₹401 Cr | ₹369.09 Cr | ₹357.84 Cr |
| Total Expenses | ₹2,124.33 Cr | ₹2,078.15 Cr | ₹2,193.96 Cr | ₹2,181.85 Cr | ₹2,290.45 Cr | ₹2,337.95 Cr | ₹2,223.5 Cr | ₹2,079.17 Cr | ₹2,237.12 Cr | ₹2,335.94 Cr | ₹2,226.06 Cr | ₹2,059.66 Cr |
| Profit Before Exceptional Items & Tax | ₹876.31 Cr | ₹799.28 Cr | ₹755.28 Cr | ₹750.09 Cr | ₹555.52 Cr | ₹632.94 Cr | ₹723.75 Cr | ₹446.24 Cr | ₹779.88 Cr | ₹687.22 Cr | ₹509.78 Cr | ₹426.04 Cr |
| Exceptional Items | ₹0 | -₹17.38 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹876.31 Cr | ₹781.9 Cr | ₹755.28 Cr | ₹750.09 Cr | ₹555.52 Cr | ₹632.94 Cr | ₹723.75 Cr | ₹446.24 Cr | ₹779.88 Cr | ₹687.22 Cr | ₹509.78 Cr | ₹426.04 Cr |
| Total Tax Expense | ₹184.08 Cr | ₹199.83 Cr | ₹173.91 Cr | ₹190.96 Cr | ₹147.35 Cr | ₹160.89 Cr | ₹186.22 Cr | ₹117.2 Cr | ₹201.21 Cr | ₹63.44 Cr | ₹130.13 Cr | ₹108.04 Cr |
| Net Profit | ₹692.23 Cr | ₹582.07 Cr | ₹581.37 Cr | ₹559.13 Cr | ₹408.17 Cr | ₹472.05 Cr | ₹537.53 Cr | ₹329.04 Cr | ₹578.67 Cr | ₹623.78 Cr | ₹415.74 Cr | ₹335.95 Cr |
| Other Comprehensive Income | ₹3.62 Cr | -₹1.19 Cr | -₹3 Lakh | -₹1.32 Cr | -₹91 Lakh | -₹1.45 Cr | -₹2.48 Cr | -₹42 Lakh | -₹36 Lakh | -₹29 Lakh | -₹2.51 Cr | ₹1.47 Cr |
| Total Comprehensive Income | ₹695.85 Cr | ₹580.88 Cr | ₹581.34 Cr | ₹557.81 Cr | ₹407.26 Cr | ₹470.6 Cr | ₹535.05 Cr | ₹328.62 Cr | ₹578.31 Cr | ₹623.49 Cr | ₹413.23 Cr | ₹337.42 Cr |
| EBITDA (computed) | ₹995.51 Cr | ₹919.63 Cr | ₹884.22 Cr | ₹880.11 Cr | ₹710.49 Cr | ₹767.41 Cr | ₹843.54 Cr | ₹564.25 Cr | ₹897.76 Cr | ₹812.82 Cr | ₹612.26 Cr | ₹517.26 Cr |
| Basic EPS | ₹11.92 | ₹10.02 | ₹10.01 | ₹9.63 | ₹7.03 | ₹8.13 | ₹9.21 | ₹5.62 | ₹9.88 | ₹10.65 | ₹6.48 | ₹5.43 |
| Diluted EPS | ₹11.92 | ₹10.02 | ₹10.01 | ₹9.63 | ₹7.03 | ₹8.13 | ₹9.21 | ₹5.62 | ₹9.88 | ₹10.65 | ₹6.48 | ₹5.43 |
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Aurobindo Pharma Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board & Governance of Aurobindo Pharma Ltd
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Aurobindo Pharma Ltd has 10 directors - 5 independent and 2 executive. The board is chaired by Mangalam Ramasubramanian Kumar.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Mangalam Ramasubramanian Kumar | Non-Executive - Independent Director · Chairperson | 2024-04-01 | 3 |
| Nithyananda Reddy Kambam | Executive Director · MD | 1986-12-26 | 1 |
| Madan Mohan Reddy Mettu | Executive Director | 2006-09-18 | 1 |
| Venkata Ramprasad Reddy Penaka | Non-Executive - Non Independent Director | 1986-12-26 | 1 |
| Sarath Chandra Reddy Penaka | Non-Executive - Non Independent Director | 2007-09-27 | 1 |
| Girish Paman Vanvari | Non-Executive - Independent Director | 2020-11-05 | 6 |
| Santanu Mukherjee | Non-Executive - Independent Director | 2023-02-09 | 4 |
| Satakarni Makkapati | Non-Executive - Non Independent Director | 2023-11-09 | 1 |
| Deepali Pant Joshi | Non-Executive - Independent Director | 2024-02-10 | 3 |
| Punita Kumar Sinha | Non-Executive - Independent Director | 2026-02-09 | 5 |
Board Committees
| Committee | Members |
|---|---|
| Audit Committee | Girish Paman Vanvari (Chairperson), Santanu Mukherjee, Nithyananda Reddy Kambam, Punita Kumar Sinha |
| Nomination and remuneration committee | Santanu Mukherjee (Chairperson), Girish Paman Vanvari, Deepali Pant Joshi, Mangalam Ramasubramanian Kumar, Satakarni Makkapati, Punita Kumar Sinha |
| Stakeholders Relationship Committee | Santanu Mukherjee (Chairperson), Nithyananda Reddy Kambam, Girish Paman Vanvari, Mangalam Ramasubramanian Kumar, Deepali Pant Joshi |
| Risk Management Committee | Girish Paman Vanvari (Chairperson), Santanu Mukherjee, Madan Mohan Reddy Mettu |
| Corporate Social Responsibility Committee | Nithyananda Reddy Kambam (Chairperson), Sarath Chandra Reddy Penaka, Girish Paman Vanvari, Deepali Pant Joshi, Mangalam Ramasubramanian Kumar |
Charges & Borrowings of Aurobindo Pharma Ltd
Open charges
₹2,000 Cr
Satisfied charges
₹4,387.54 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jun 1997 | State Bank of India | ₹2,000 Cr | Open |
| 08 Jan 2013 | Dbs Bank Ltd | ₹164 Cr | Satisfied |
| 25 May 2012 | Ifci Limited | ₹156 Cr | Satisfied |
| 25 May 2012 | Ifci Limited | ₹130 Cr | Satisfied |
| 28 Feb 2011 | Axis Bank Limited | ₹37.98 Cr | Satisfied |
Total charge records: 44 View all charges
Employees and EPFO Compliance at Aurobindo Pharma Ltd
View historical data on people associated with Aurobindo Pharma Ltd, including employment history and EPFO contributions.
Employee Count & EPFO Data of Aurobindo Pharma Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification
GST Compliance of Aurobindo Pharma Ltd
XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS
GSTIN & GST Filing Data of Aurobindo Pharma Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution
Credit Ratings, Litigation & Regulatory Alerts for Aurobindo Pharma Ltd
Credit rating
2015
2017
2019
2021
2023
Litigation
District Court
35
High Court
45
Supreme Court
0
NCLT / NCLAT
0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults
Credit Ratings, Legal Cases & Regulatory Alerts of Aurobindo Pharma Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)
MSME Payment Delays by Aurobindo Pharma Ltd
MSME Payment Delays by Aurobindo Pharma Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal
Subsidiaries & Group Companies of Aurobindo Pharma Ltd
Subsidiaries & Group Companies of Aurobindo Pharma Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Aurobindo Pharma Ltd with ownership details.
Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year
MCA Filings & Documents of Aurobindo Pharma Ltd
MCA Filings & Documents of Aurobindo Pharma Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates
Recent Activity on Aurobindo Pharma Ltd
Activity
10 Sep 2025
Aurobindo Pharma Ltd last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Aurobindo Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
01 Apr 2024
Mangalam Ramasubramanian Kumar was appointed as a Director on 01 Apr 2024 & has been associated with this company since 2 years 3 months.
Directors
10 Feb 2024
Deepali Pant Rajeev Joshi was appointed as a Director on 10 Feb 2024 & has been associated with this company since 2 years 4 months.
Directors
09 Nov 2023
Satakarni Makkapati was appointed as a Director on 09 Nov 2023 & has been associated with this company since 2 years 7 months.
Charges
22 Feb 2023
A charge with State Bank Of India of Rs. 2,000.00 Cr registered on 05 Jun 1997 with Charge ID 80013576 was modified on 22 Feb 2023.
Recent News on Aurobindo Pharma Ltd
Frequently Asked Questions about Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 26 December 1986 (40+ years old) and is registered under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA. The company has 15,925 employees.
Aurobindo Pharma Ltd reported revenue of ₹32,346 Cr for FY 2025 (up 9.00% YoY).
The current directors of Aurobindo Pharma Ltd are:
- Adi Reddy Baddigam
- Santanu Mukherjee
- Deepali Pant Rajeev Joshi
- Nityananda Reddy Kambam
- Madan Mohan Reddy Mettu
- Venkata Ramprasad Reddy Penaka
- Satakarni Makkapati
- Girish Paman Vanvari
- Santhanam Subramanian
- Mr B Adi Reddy
- Sarath Chandra Reddy Penaka
- Mangalam Ramasubramanian Kumar
- Mr Ssubramanian
- Santhanam Subramanian
- Adi Reddy Baddigam
The primary industry of Aurobindo Pharma Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Aurobindo Pharma Ltd is listed on both BSE (code: 524804) and NSE (symbol: AUROPHARMA).
Aurobindo Pharma Ltd can be reached at the registered office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038, or through the website aurobindo.com.